Quality & Compliance / Pharmaceutical Manufacturing

Technology Transfer: Moving a Validated Process Without Breaking It

A process validated at one site, or a method validated in one lab, means little the moment it moves somewhere else. Technology transfer is how that validated state survives the move.

⏱ 10 min read 📋 WHO TRS 1044, Annex 4 🔁 Site-to-Site & R&D-to-Manufacturing Transfer

In this guide

1. Why the series ends up here
2. The regulatory foundations
3. The technology transfer lifecycle
4. Approaches to analytical method transfer
5. Comparative testing acceptance calculator
6. Technology transfer self-check
7. Where transfers fail inspection
8. Specimen quality forms
9. References

01Why the series ends up here

A process validated at a development site, a cleaning limit calculated for one piece of equipment, an analytical method qualified in one laboratory — none of that automatically survives a move to a new site, a new team, or a scaled-up batch size. Technology transfer is the discipline that carries validated knowledge across that gap deliberately, rather than assuming it travels on its own.

WHO defines technology transfer as a logical, documented procedure that controls the transfer of a process, together with its documentation and professional expertise, between development and manufacture, or between manufacturing sites.^1,2 The 2022 update to WHO's guidelines folded in the same ICH lifecycle thinking that runs through process validation, analytical method validation and quality risk management — the same threads this entire series has been pulling on.^3,4

A sending unit (SU) — often R&D or an originating manufacturing site — and a receiving unit (RU) are both involved, and success is measured not just by documentation changing hands, but by the RU demonstrating it can actually reproduce the critical elements of the transferred process to everyone's satisfaction, including the applicable regulator's.¹

TT

Recommended reading

Technology Transfer: Drug Product Manufacturing Process (AAPS Introductions in the Pharmaceutical Sciences)

A concise, current reference specifically on drug product manufacturing technology transfer, addressing the same ICH lifecycle alignment across FDA, EMA, WHO and PIC/S that shapes the framework covered below.

Find it on Amazon →

02The regulatory foundations

Framework	Issuing body	Core contribution
WHO Technical Report Series 961, Annex 7 (2011)	World Health Organization	Original WHO guidelines on transfer of technology in pharmaceutical manufacturing1,2
WHO Technical Report Series 1044, Annex 4 (2022)	World Health Organization	Updated guidelines aligning technology transfer with the ICH Q8–Q12 lifecycle approach and adding due diligence/gap analysis3,4,5
ICH Q10 & Q12	International Council for Harmonisation	Pharmaceutical quality system and lifecycle management principles the WHO update explicitly incorporates4

The 2022 revision restructured the guidance around a clearer set of project phases and added an explicit due-diligence and gap-analysis step before planning even begins — a recognition that many transfer failures trace back to gaps identified too late, after the receiving unit was already committed to a timeline.^4,5

03The technology transfer lifecycle

WHO's updated guidance organizes a transfer project into three phases.^4,5 Click each to expand it.

Due diligence and gap analysis compare the sending unit's process, equipment, and quality system against the receiving unit's capabilities, surfacing differences — equipment scale, utilities, personnel experience — before any commitment is made.

• Gap analysis conducted before the receiving unit commits to a timeline
• Roles and responsibilities between SU and RU defined up front

A technology transfer protocol is developed defining what will be transferred, how success will be measured, and what qualification, validation and comparative testing will be required — drawing directly on the risk management principles covered earlier in this series.

• Critical process parameters, critical quality attributes and control strategy documented and shared
• Acceptance criteria for comparative/bridging studies agreed before execution

The process (production, packaging, cleaning) and analytical procedures are executed at the receiving unit, with results compared against the sending unit's historical performance and the protocol's predefined acceptance criteria.

• Production and QC method transfer both addressed, not just one or the other
• Results feed into a formal transfer report, closing the loop against Phase 1's gap analysis

Multi

Recommended reading

Pharmaceutical Technology Transfer: A Multidimensional Learning Approach

Walks through the steps, documentation, and common failure factors of a transfer project end to end — a useful applied companion to the phase structure above.

Find it on Amazon →

04Approaches to analytical method transfer

Moving a validated analytical method to a new lab doesn't have a single required approach — the strategy depends on risk and how much the method or matrix has changed. Switch tabs to compare the common options.

Comparative (side-by-side) testing. The most common approach: both the sending and receiving labs test the same samples using the same method, and results are compared against predefined statistical acceptance criteria — the scenario the calculator below is built around.

Co-validation. The receiving lab participates in the original method validation study itself, generating data at both sites simultaneously — useful when the method and receiving lab are both new.

Revalidation. The receiving lab performs a full or partial revalidation of the method, typically warranted when the transfer coincides with a significant method or matrix change rather than a simple site move.

Transfer waiver. No comparative testing is performed, justified by a documented risk assessment — appropriate only for low-risk methods (e.g., a simple, well-characterized compendial test) with strong existing evidence of robustness.

05Comparative testing acceptance calculator

For a side-by-side method transfer, one common acceptance approach compares the percent difference between the sending and receiving unit's mean results against a predefined limit. Enter results from both labs to see an illustrative comparison.

Method transfer mean comparison interactive

% Difference = |RU mean − SU mean| ÷ SU mean × 100. A commonly cited illustrative acceptance range for assay-type methods is within about 2% absolute difference, though the real limit must be defined in your protocol based on the method's own validated precision and the product's specification.

Sending unit (SU) mean result

Receiving unit (RU) mean result

Acceptance limit (% difference)

Pooled SD (optional, for reference)

–

% difference between means

–

Ratio to acceptance limit

Enter both mean results to compare.

This is a simplified illustrative comparison, not a validated statistical acceptance test. A real comparative testing protocol should define acceptance criteria in advance (often via a two one-sided t-test, confidence interval approach, or method-specific precision data) and account for sample size — never rely on this tool alone to accept or reject a method transfer.

Q10

Recommended reading

ICH Quality Guidelines: An Implementation Guide

Covers the Q10/Q12 lifecycle and change management principles that WHO's 2022 technology transfer update explicitly builds on, plus the quality risk management approach behind Phase 1's gap analysis.

Find it on Amazon →

06Technology transfer self-check

Readiness checklist

Due diligence / gap analysis completed before the receiving unit commits to a timeline

Critical process parameters, CQAs and control strategy documented and shared with the receiving unit

Analytical method transfer approach (comparative, co-validation, revalidation, waiver) selected with documented rationale

Acceptance criteria for comparative/bridging studies agreed before execution, not after

Receiving unit's equipment and facility qualification status confirmed before transfer execution

Both production and QC method transfer addressed, not just one

Formal transfer report closes the loop against the original gap analysis

0 of 7 complete

07Where transfers fail inspection

• Skipping or rushing the gap analysis. Committing to a transfer timeline before understanding the differences between sending and receiving units is one of the most common root causes of a failed or delayed transfer.^4,5
• Acceptance criteria written after the data comes in. Comparative testing criteria set retroactively to match whatever results happened to come out undermines the point of a predefined acceptance approach.
• Production transferred, method transfer forgotten. A process that moves sites without a parallel, deliberate transfer of the analytical methods testing it leaves the receiving unit unable to reliably confirm its own output.
• No closure against the original plan. A transfer report that doesn't reference back to the initial gap analysis and protocol makes it hard to demonstrate the transfer achieved what it set out to.

Worth remembering: technology transfer is where nearly every other topic in this series shows up at once — qualification status at the receiving site, method validation bridging data, risk-based planning, and change control governing what happens afterward. It's less a standalone activity than the moment this whole series gets tested together.

08Specimen quality forms

A gap analysis / transfer protocol summary and a comparative testing results record — the two documents that typically anchor a technology transfer package end to end.

Form TT-01 — Gap Analysis & Transfer Protocol Summary

Specimen only — not a controlled document. Full protocol should define detailed acceptance criteria and a complete equipment/facility comparison.

Product / process / method

Sending unit (SU)

Receiving unit (RU)

Transfer type (site-to-site / R&D-to-manufacturing)

Area compared	Gap identified?	Action required
Equipment / scale
Facility / utilities qualification status
Personnel training / experience
Analytical method transfer approach

Prepared by / date

Reviewed by (QA) / date

Approved by / date

Form TT-02 — Comparative Testing Results Record

Specimen only — for recording side-by-side SU/RU results against predefined acceptance criteria.

Method / test

Acceptance criterion

Sample	SU result	RU result	% difference	Pass / Fail

Performed by (RU) / date

Reviewed by (SU) / date

Approved by (QA) / date

These specimen forms illustrate typical content only. Your quality system's document control procedure — numbering, revision history, approval routing — takes precedence over this format.

09References

1. World Health Organization. WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series, No. 961, Annex 7, 2011. extranet.who.int
2. World Health Organization. TRS 961, Annex 7 (full text). extranet.who.int
3. World Health Organization. TRS 1044 – Annex 4: WHO Guidelines on Technology Transfer in Pharmaceutical Manufacturing. April 2022. who.int
4. gmp-compliance.org. "WHO TRS1044-Annex4: Technology Transfer in Pharmaceutical Manufacturing" (full text). gmp-compliance.org
5. gmp-compliance.org. "WHO: Updates on Method Transfer." gmp-compliance.org

Disclosure: This article contains Amazon affiliate links. As an Amazon Associate, this site may earn from qualifying purchases at no extra cost to you. Recommendations reflect genuine, independent picks specific to technology transfer and method transfer practice — they are not a substitute for your organization's own quality and regulatory guidance.

This content is for general professional education and does not constitute regulatory or legal advice. The comparative testing calculator is a simplified illustrative estimate and must not be used as the sole basis for accepting a real method transfer — use a properly defined statistical acceptance approach and validated software for actual decisions.

Page source (HTML)

Quality & Compliance / Pharmaceutical Manufacturing

Supplier & Vendor Qualification: Trusting What You Didn't Make Yourself

Every validation activity in this series assumes the raw materials, components and outsourced services feeding into it are what they claim to be. Supplier qualification is where that assumption actually gets earned.

⏱ 10 min read 📋 21 CFR 211.84 / ICH Q10 🤝 Supplier & Vendor Management

In this guide

1. Why qualification runs upstream too
2. The regulatory foundations
3. The supplier qualification lifecycle
4. Tiered oversight by criticality
5. Supplier risk scoring tool
6. Supplier qualification self-check
7. Where programs fail inspection
8. Specimen quality forms
9. References

01Why qualification runs upstream too

Equipment and facility qualification, covered earlier in this series, proves the room and the machine are ready. Supplier qualification asks the same question one step further back: is the raw material, component, or outsourced service arriving at your dock — or performed on your behalf — actually what it claims to be?

A cleaning validation limit, a process validation batch, a stability study — every one of them assumes the active ingredient, excipient, or container closure that went into the batch met its specification before manufacturing even started. That assumption isn't automatic; it's the direct output of a supplier qualification program.

U.S. CGMP regulations require each lot of components, drug product containers and closures to be withheld from use until sampled, tested and released by the quality control unit, with the sampling plan itself explicitly informed by the supplier's past quality history.^1,3 ICH Q10 goes further, framing ongoing supplier evaluation and monitoring as a management responsibility within the broader pharmaceutical quality system, not a one-time receiving-dock activity.²

211

Recommended reading

Good Manufacturing Practices for Pharmaceuticals

Covers Subpart E of 21 CFR 211 — the receiving, testing and approval requirements for components, containers and closures this post is built around — alongside the rest of the CGMP framework it sits inside.

Find it on Amazon →

02The regulatory foundations

Framework	Issuing body	Core contribution
21 CFR 211.84 & 211.80–211.94 (Subpart E)	U.S. FDA	Requires testing/release of each lot of components, containers and closures before use, informed by supplier quality history1,3
ICH Q10 — Pharmaceutical Quality System	International Council for Harmonisation	Frames supplier and outsourced-activity oversight as an ongoing management responsibility within the quality system2
Q&A: CGMP — Control of Components and Drug Product Containers and Closures	U.S. FDA (CDER)	Clarifies practical expectations, including when reduced or certificate-of-analysis-based testing is appropriate4

FDA's own guidance is explicit that once a supplier's reliability has been established — through validation of their test results against the buyer's own testing — a manufacturer may rely more heavily on the supplier's certificate of analysis, with visual identification performed on receipt rather than full re-testing of every attribute.⁴ That flexibility is earned through documented supplier qualification, not assumed by default.

03The supplier qualification lifecycle

Like every other qualification activity in this series, supplier qualification is a lifecycle, not a one-time approval. Click each stage to expand it.

Before first use, a new supplier is evaluated — questionnaire, document review, and for higher-risk materials or services, an on-site or remote audit — against defined criteria before being added to an approved supplier list.

• Criticality of the material or service drives the depth of qualification
• Approved supplier list maintained as a controlled document

Incoming lot testing results, certificates of analysis, and any supplier-related deviations or complaints are tracked over time — the supplier equivalent of the continued process verification covered in earlier posts.

• Trend supplier performance, not just individual lot pass/fail
• Reduced testing programs revisited if trends degrade

Suppliers are reassessed on a defined schedule — commonly annually for critical materials — or triggered by a significant event: a quality failure, a site change at the supplier, or a regulatory action against them.

• Requalification frequency risk-based on material/service criticality
• Supplier-side change control changes routed into the buyer's own change control system

Q10

Recommended reading

ICH Quality Guidelines: An Implementation Guide

Covers how ICH Q10's outsourced activities and purchased materials expectations connect supplier management to the rest of the pharmaceutical quality system, including change management and management review.

Find it on Amazon →

04Tiered oversight by criticality

Not every supplier warrants the same depth of qualification. Most programs tier oversight by how directly the material or service affects product quality. Switch tabs to compare typical tiers.

Critical. Active pharmaceutical ingredients, primary packaging in direct product contact, and outsourced manufacturing or testing. Typically requires an on-site audit before approval, full incoming testing initially, and annual or event-triggered requalification.

Major. Key excipients, secondary packaging with some product-contact risk, or calibration/qualification service providers. Often qualified through document review plus a remote or periodic audit, with reduced testing once reliability is established.

Minor. Non-product-contact items — shipping materials, general facility services. Typically qualified through a documented questionnaire or certificate review alone, without a full audit.

05Supplier risk scoring tool

This interactive tool illustrates how a criticality-based risk score might inform qualification depth — not a substitute for a documented supplier risk assessment. Check the factors that apply to a given supplier or material.

Illustrative supplier risk scorer interactive

Select every factor that applies to this supplier or material.

Active pharmaceutical ingredient or drug substance supplier

Sole source — no qualified alternative supplier available

Material is in direct contact with the drug product

Outsourced manufacturing, testing, or sterilization activity

No prior quality history with this supplier

Material used in a non-critical, indirect process step

Supplier has an established, positive quality track record with your site

Select factors above

Check the boxes that describe the supplier or material to see an illustrative oversight tier.

This is a simplified teaching illustration, not a validated risk assessment tool. Real supplier qualification decisions require a documented risk assessment against your own specifications, regulatory filings and quality system — never rely on this tool alone to decide audit scope or testing frequency.

FMEA

Recommended reading

Quality Risk Management in the FDA-Regulated Industry

The risk-assessment tools behind a real supplier risk scoring exercise, covered in far more depth than the illustrative calculator above.

Find it on Amazon →

06Supplier qualification self-check

Readiness checklist

Approved supplier list maintained as a controlled document, tiered by criticality

Initial qualification depth (questionnaire, document review, audit) proportionate to risk

Reduced testing programs justified by documented, validated supplier reliability

Ongoing performance (lot results, deviations, complaints) trended, not just archived

Periodic requalification scheduled and risk-based on criticality

Supplier-side changes flow into your own change control system

Outsourced manufacturing/testing activities covered by a quality agreement

0 of 7 complete

07Where programs fail inspection

• Reduced testing without earned justification. Relying on a certificate of analysis alone, without first validating that supplier's results against your own testing, isn't the flexibility FDA guidance actually describes.⁴
• Approved supplier lists that drift out of date. A supplier still listed as approved after a significant quality event, site change, or years without requalification is a recurring inspection finding.
• Supplier changes that bypass change control. A supplier's own process, site, or raw material sourcing change that reaches your manufacturing floor without ever entering your change control system defeats the purpose of qualifying them in the first place.
• Audits that check a box rather than assess risk. A supplier audit performed on schedule but without meaningful follow-up on findings provides documentation, not assurance.

Worth remembering: supplier qualification is where several threads from this series meet — quality risk management to tier oversight, change control to catch supplier-side changes, and the same continued-verification mindset used for processes and equipment, applied to a relationship you don't directly control.

08Specimen quality forms

A supplier qualification/audit summary and an ongoing performance monitoring log — the working documents behind a typical approved supplier file.

Form SQ-01 — Supplier Qualification & Audit Summary

Specimen only — not a controlled document. Full audit report and CAPA responses should be attached as supporting documentation.

Supplier name

Material / service supplied

Criticality tier (Critical / Major / Minor)

Qualification method (audit / document review / questionnaire)

Key findings / observations

Approval status

Next requalification due date

Assessed by / date

Reviewed by (QA) / date

Approved by / date

Form SQ-02 — Ongoing Supplier Performance Monitoring Log

Specimen only — updated as lots are received and reviewed.

Lot / shipment date	Incoming test result	Deviation / complaint?	Trend note

These specimen forms illustrate typical content only. Your quality system's document control procedure — numbering, revision history, approval routing — takes precedence over this format.

09References

1. Cornell Law School, Legal Information Institute. "21 CFR § 211.84 — Testing and Approval or Rejection of Components, Drug Product Containers, and Closures." law.cornell.edu
2. U.S. Food and Drug Administration. "Control of Components and Drug Product Containers and Closures" (training slides referencing ICH Q10). fda.gov
3. eCFR. "§ 211.84 Testing and Approval or Rejection of Components, Drug Product Containers, and Closures." ecfr.gov
4. U.S. Food and Drug Administration. Questions and Answers: Current Good Manufacturing Practices — Control of Components and Drug Product Containers and Closures. fda.gov
5. Zamann Pharma Support. "21 CFR 211.84: Testing and Approval of Components, Drug Product Containers, and Closures." zamann-pharma.com

Disclosure: This article contains Amazon affiliate links. As an Amazon Associate, this site may earn from qualifying purchases at no extra cost to you. Recommendations reflect genuine, independent picks for readers building or auditing a supplier qualification program — they are not a substitute for your organization's own quality and regulatory guidance.

This content is for general professional education and does not constitute regulatory or legal advice. The supplier risk scoring tool is a simplified illustrative aid and must never be relied upon alone to determine qualification depth, audit scope, or testing frequency — consult your quality risk management process and applicable regulatory guidance for real decisions.

Page source (HTML)